{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:52:34Z","timestamp":1791337954356,"version":"4.3.1"},"reference-count":44,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and morbidity. The treatment of AI in the last years has been object of important changes due to the development of a dual-release preparation of hydrocortisone. It differs from previous therapeutic strategy as it contemplates a once-daily tablet that allows more closely mimicking the physiological circadian cortisol rhythm. The aim of the study was to evaluate the effects of dual-release hydrocortisone treatment on the glycometabolic profile and health-related quality of life of patients with AI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Methods<\/jats:title>\n                    <jats:p>In this clinical open trial, we enrolled ten patients with primary AI (41\u2009\u00b1\u20092.67\u2009years) and nine patients with AI secondary to hypopituitarism (53.2\u2009\u00b1\u200917.7\u2009years). We evaluated the glycometabolic profile before and 3, 6, 9 and 12\u2009months after dual-release hydrocortisone administration. We also evaluated health-related quality of life, estimated by the AddiQol questionnaire. The mean dose administered of dual-release hydrocortisone was 28.33\u2009\u00b1\u20096.68\u2009mg\/day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One female hypopituitary patient dropped out from the study. After 12\u2009months of treatment, the mean dosage administered of dual-release hydrocortisone was significantly lower (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) and all patients reported improved quality of life and well-being. The glycometabolic profile improved and the glycosylated hemoglobin decreased significantly in patients with primary AI (6.25\u2009\u00b1\u20090.2 vs 5.35\u2009\u00b1\u20090.17,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). In contrast, hypopituitary patients had worse glycometabolic profile and a trend toward hypertriglyceridemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dual-release hydrocortisone treatment improved the quality of life of patients with AI, and it allowed a decrease of cortisol dosage administered in the absence of side effects. The glycometabolic profile worsened in hypopituitary patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-17-0368","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T20:10:52Z","timestamp":1513109452000},"page":"211-219","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":30,"title":["Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life"],"prefix":"10.1530","volume":"7","author":[{"given":"L M","family":"Mongio\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"La Vignera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref11","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(03)13492-7","article-title":"Adrenal insufficiency","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study","volume":"161","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1210\/jc.2007-0685","article-title":"Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis","volume":"92","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/BF03345773","article-title":"Metabolic and cardiovascular profile in patients with Addison\u2019s disease under conventional glucocorticoid replacement","volume":"32","year":"2009","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref361","doi-asserted-by":"publisher","first-page":"201645","DOI":"10.1016\/j.lpm.2016.05.007","article-title":"Therapeutic innovations in endocrine diseases part modified - release glucocorticoid compounds : what good do they provide to the adrenal insufficient patient Presse https org","author":"ReznikY"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/joim.12162","article-title":"Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency","volume":"275","year":"2014","journal-title":"Journal of Internal Medicine"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1210\/jc.2006-0076","article-title":"Premature mortality in patients with Addison\u2019s disease: a population-based study","volume":"91","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12020-015-0681-z","article-title":"Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison\u2019s disease","volume":"51","year":"2016","journal-title":"Endocrine"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1210\/jc.2007-0685","article-title":"Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis","volume":"92","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/EJE-14-0327","article-title":"Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency","volume":"171","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","article-title":"Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties","volume":"57","year":"2002","journal-title":"Clinical Endocrinology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone","volume":"160","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(03)13492-7","article-title":"Adrenal insufficiency","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/EJE-09-0884","article-title":"Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies","volume":"162","year":"2010","journal-title":"European Journal of Endocrinology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0033-1351259","article-title":"Increased cardiovascular risk in South African patients with Addison\u2019s disease","volume":"45","year":"2013","journal-title":"Hormone and Metabolic Research"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/EJE-14-1114","article-title":"Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency","volume":"172","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone","volume":"160","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/EJE-14-1114","article-title":"Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency","volume":"172","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2009-1711","article-title":"Development of a disease-specific quality of life questionnaire in Addison\u2019s disease","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref221","doi-asserted-by":"publisher","first-page":"20163","DOI":"10.1530\/EJE-15-1242","article-title":"Management of endocrine disease quality of life and complications of primary adrenal insufficiency a of https org","journal-title":"epidemiology review European Journal Endocrinology"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study","volume":"161","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/EJE-14-0327","article-title":"Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency","volume":"171","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e90768","DOI":"10.1371\/journal.pone.0090768","article-title":"Cardiovascular risk factors in patients with Addison\u2019s disease: a comparative study of South African and Swedish patients","volume":"9","year":"2014","journal-title":"PLoS ONE"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/EJE-09-0884","article-title":"Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies","volume":"162","year":"2010","journal-title":"European Journal of Endocrinology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/BF03345773","article-title":"Metabolic and cardiovascular profile in patients with Addison\u2019s disease under conventional glucocorticoid replacement","volume":"32","year":"2009","journal-title":"Journal of Endocrinological Investigation"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire","volume":"158","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire","volume":"158","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2009-1711","article-title":"Development of a disease-specific quality of life questionnaire in Addison\u2019s disease","volume":"95","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"e90768","DOI":"10.1371\/journal.pone.0090768","article-title":"Cardiovascular risk factors in patients with Addison\u2019s disease: a comparative study of South African and Swedish patients","volume":"9","year":"2014","journal-title":"PLoS ONE"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/joim.12162","article-title":"Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency","volume":"275","year":"2014","journal-title":"Journal of Internal Medicine"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12020-015-0681-z","article-title":"Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison\u2019s disease","volume":"51","year":"2016","journal-title":"Endocrine"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1210\/jc.2011-1901","article-title":"Quality of life in European patients with Addison\u2019s disease: validity of the disease-specific questionnaire AddiQoL","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref01","doi-asserted-by":"publisher","first-page":"20163","DOI":"10.1530\/EJE-15-1242","article-title":"Management of endocrine disease quality of life and complications of primary adrenal insufficiency a of https org","journal-title":"epidemiology review European Journal Endocrinology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1210\/jc.2006-0076","article-title":"Premature mortality in patients with Addison\u2019s disease: a population-based study","volume":"91","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"201645","DOI":"10.1016\/j.lpm.2016.05.007","article-title":"Therapeutic innovations in endocrine diseases part modified - release glucocorticoid compounds : what good do they provide to the adrenal insufficient patient Presse https org","author":"ReznikY"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2265.2002.01597.x","article-title":"Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties","volume":"57","year":"2002","journal-title":"Clinical Endocrinology"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0033-1351259","article-title":"Increased cardiovascular risk in South African patients with Addison\u2019s disease","volume":"45","year":"2013","journal-title":"Hormone and Metabolic Research"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1210\/jc.2011-1901","article-title":"Quality of life in European patients with Addison\u2019s disease: validity of the disease-specific questionnaire AddiQoL","volume":"97","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/7\/1\/EC-17-0368.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/7\/1\/EC-17-0368.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:42:42Z","timestamp":1784554962000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/7\/1\/211-219\/242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":44,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/ec-17-0368","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}